よむ、つかう、まなぶ。
07【参考資料２】肺炎球菌コンジュゲートワクチン（小児用）作業チーム報告書 (29 ページ)
出典
| 公開元URL | https://www.mhlw.go.jp/stf/newpage_40343.html |
| 出典情報 | 厚生科学審議会 予防接種・ワクチン分科会 予防接種基本方針部会 ワクチン評価に関する小委員会（第25回 5／23）《厚生労働省》 |
ページ画像
ダウンロードした画像を利用する際は「出典情報」を明記してください。
低解像度画像をダウンロード
プレーンテキスト
資料テキストはコンピュータによる自動処理で生成されており、完全に資料と一致しない場合があります。
テキストをコピーしてご利用いただく際は資料と付け合わせてご確認ください。
pneumococcal diseases in France, 2001-2006. Euro Surveill 28:13, 2008.
15. Rükinger S et al. Reduction in the incidence of invasive pneumococcal
disease after general vaccination with 7-valent pneumococcal conjugate
vaccine in Germany. Vaccine 27:4136-4141, 2009.
16. Vestrheim DF et al. Effectiveness of a 2+1 dose schedule pneumococcal
conjugate vaccination programme on invasive pneumococcal disease
among children in Norway. Vaccine 26:3277-3281, 2008.
17. Grijalva CG et al. Decline in pneumonia admissions after routine
childhood immunization with pneumococcal conjugate vaccine in the USA:
a time-series analysis. Lancet 369:1179-1186, 2007.
18. 医薬品医療機器総合機構 プレベナー審査報告書
www.info.pmda.go.jp/shinyaku/P200900053/53039600_22100AMX02255_A100_1.pdf
19. 神谷齊ほか. 小児用 7 価肺炎球菌結合型ワクチンの医療経済効果. 小児科臨
床 61: 2233-2241, 2008.
20. Lieu TA, et al. Projected cost-effectiveness of pneumococcal conjugate
vaccination of healthy infants and young children. JAMA 283:1460-1468
2000.
21. Ray GT, et al. Cost-effectiveness of pneumococcal conjugate vaccine:
evidence from the first 5 years of use in the United States incorporating
herd effects. Pediatr Infect Dis J 25:494-501 2006
22. McIntosh ED, et al. The cost-burden of paediatric pneumococcal disease
in the UK and the potential cost-effectiveness of prevention using 7-valent
pneumococcal conjugate vaccine.Vaccine 21:2564-2572 2003.
23. McIntosh ED, et al. Pneumococcal pneumonia in the UK--how herd
immunity affects the cost-effectiveness of 7-valent pneumococcal conjugate
vaccine (PCV). Vaccine 23:1739-1745 2005.
24. Melegaro A, et al. Cost-effectiveness analysis of pneumococcal conjugate
vaccination in England and Wales. Vaccine 22:4203-4214 2004.
25. Asensi F, et al. A pharmacoeconomic evaluation of seven-valent
pneumococcal conjugate vaccine in Spain. Value Health 7:36-51 2004.
26. Navas E, et al. Cost-benefit and cost-effectiveness of the incorporation of
the pneumococcal 7-valent conjugated vaccine in the routine vaccination
schedule of Catalonia (Spain).Vaccine 23:2342-2348 2005.
27. Wisløff T, et al. Cost effectiveness of adding 7-valent pneumococcal
conjugate (PCV-7) vaccine to the Norwegian childhood vaccination
program.Vaccine 24:5690-5699 2006.
28
15. Rükinger S et al. Reduction in the incidence of invasive pneumococcal
disease after general vaccination with 7-valent pneumococcal conjugate
vaccine in Germany. Vaccine 27:4136-4141, 2009.
16. Vestrheim DF et al. Effectiveness of a 2+1 dose schedule pneumococcal
conjugate vaccination programme on invasive pneumococcal disease
among children in Norway. Vaccine 26:3277-3281, 2008.
17. Grijalva CG et al. Decline in pneumonia admissions after routine
childhood immunization with pneumococcal conjugate vaccine in the USA:
a time-series analysis. Lancet 369:1179-1186, 2007.
18. 医薬品医療機器総合機構 プレベナー審査報告書
www.info.pmda.go.jp/shinyaku/P200900053/53039600_22100AMX02255_A100_1.pdf
19. 神谷齊ほか. 小児用 7 価肺炎球菌結合型ワクチンの医療経済効果. 小児科臨
床 61: 2233-2241, 2008.
20. Lieu TA, et al. Projected cost-effectiveness of pneumococcal conjugate
vaccination of healthy infants and young children. JAMA 283:1460-1468
2000.
21. Ray GT, et al. Cost-effectiveness of pneumococcal conjugate vaccine:
evidence from the first 5 years of use in the United States incorporating
herd effects. Pediatr Infect Dis J 25:494-501 2006
22. McIntosh ED, et al. The cost-burden of paediatric pneumococcal disease
in the UK and the potential cost-effectiveness of prevention using 7-valent
pneumococcal conjugate vaccine.Vaccine 21:2564-2572 2003.
23. McIntosh ED, et al. Pneumococcal pneumonia in the UK--how herd
immunity affects the cost-effectiveness of 7-valent pneumococcal conjugate
vaccine (PCV). Vaccine 23:1739-1745 2005.
24. Melegaro A, et al. Cost-effectiveness analysis of pneumococcal conjugate
vaccination in England and Wales. Vaccine 22:4203-4214 2004.
25. Asensi F, et al. A pharmacoeconomic evaluation of seven-valent
pneumococcal conjugate vaccine in Spain. Value Health 7:36-51 2004.
26. Navas E, et al. Cost-benefit and cost-effectiveness of the incorporation of
the pneumococcal 7-valent conjugated vaccine in the routine vaccination
schedule of Catalonia (Spain).Vaccine 23:2342-2348 2005.
27. Wisløff T, et al. Cost effectiveness of adding 7-valent pneumococcal
conjugate (PCV-7) vaccine to the Norwegian childhood vaccination
program.Vaccine 24:5690-5699 2006.
28